 NEW YORK, Feb. 24, 2022 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2021. 